Business Context and Reporting Period
This Form 8-K was filed by Avista Healthcare Public Acquisition Corp. (AHPAC) on December 11, 2017. The filing serves as a Regulation FD disclosure regarding a proposed business combination between AHPAC and Envigo International Holdings, Inc. (Envigo). Upon completion, AHPAC will become the ultimate parent company of Envigo. The filing incorporates an investor presentation dated December 2017 by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that it contains forward-looking estimated financial information and non-GAAP measures (EBITDA, Adjusted EBITDA) but does not list the actual figures within the text of the 8-K itself. These metrics are contained in the attached Exhibit 99.1 (Investor Presentation), which is not included in the provided source text.
Material Changes
There are no historical financial comparisons or material changes in operating results reported in this document. The filing focuses entirely on the announcement of the proposed transaction and the associated regulatory disclosures rather than reporting on past performance changes.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The filing includes forward-looking statements regarding the anticipated benefits of the business combination, including growth strategies and performance expectations. Management utilizes non-GAAP measures like EBITDA for trend analysis and budgeting, though the filing notes these are not GAAP alternatives.
Risks and Contingencies: The document outlines significant risks that could cause actual results to differ from expectations, including:
- Termination of the Transaction Agreement.
- Failure to obtain stockholder approval or meet closing conditions.
- Inability to meet listing standards post-combination.
- Operational disruption to Envigo during the transaction process.
- Competition and the ability to retain key employees and customers.
- Changes in laws or regulations.
Unusual Items: The filing includes a disclaimer that the information is not an offer to sell securities and that the investor presentation is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial figures (Revenue, EBITDA, Debt) in the Exhibit 99.1 Investor Presentation, as they are not listed in the 8-K text.
- Review the preliminary and definitive proxy statements for detailed information on the transaction terms and voting procedures.
- Confirm the status of stockholder approval required to close the business combination.
- Assess the non-GAAP reconciliations provided in the investor presentation to understand the difference between reported GAAP and adjusted metrics.
- Monitor for updates on listing standards compliance for the combined entity.